Besides metastasis at diagnosis, the Estrogen and Progesterone Receptor (ER/PR) status and the size of the primary tumor are also found to directly affect the vital prognosis of patients, Figure S9A. In particular, iMIIC infers that ER status reduces the risk of death due to breast cancer from 17.7% (ER-) to 5.4% (ER+), with a large indirect contribution (82%) from PR status. Here, PGR is linked to breast cancer.